NDA 013025 · Hospira
Tham
Tromethamine, Potassium Chloride, Sodium Chloride · Injection
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Nov 8, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1965
Dec 16, 1965
Approved uses
1
Original approval plus efficacy supplements
Registered trials
380
73 Phase 3, 25 recruiting
FAERS reports
179
109 serious, 14 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 27, 2026.
INDICATIONS AND USAGE Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 16, 1965 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review
2 products under this application
- THAM · TROMETHAMINE 18GM/500ML (3.6GM/100ML) · SOLUTION, INJECTION · Prescription · TE AP
- THAM-E · POTASSIUM CHLORIDE 370MG/VIAL; SODIUM CHLORIDE 1.75GM/VIAL; TROMETHAMINE 36GM/VIAL · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tromethamine" as an intervention, any sponsor and status, largest first.
- MVA-BN-RSV Vaccine TrialPivotal-lookingTerminated
Bavarian NordicIndustry
NCT05238025 · 20,419 participants · Start Apr 19, 2022 · Primary completion Jun 29, 2023
Drug: MVA-BN-RSV vaccine; Tris Buffered Saline (TBS) · For: Respiratory Syncytial Virus Infections
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 120 sites in all
Serum Institute of India Pvt. Ltd.Industry
NCT04358731 · 1,640 participants · Start Dec 27, 2019 · Primary completion Mar 24, 2021
Drug: NmCV-5; Menactra · For: Vaccine for Meningococcal Disease
Sites: Bangalore, India; Mumbai, India; Pune, India · 11 sites in all
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.Pivotal-lookingCompleted
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT04959331 · 1,000 participants · Start Nov 2, 2021 · Primary completion Dec 14, 2024
Drug: Fosfomycin Trometamol Salt; Nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Calatayud, Spain; Zaragoza, Spain; Calvià, Spain · 33 sites in all
- ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell LymphomaPivotal-lookingStatus unknown
Prof. Dr. M. Dreyling (co-chairman)Academic, hospital or other
NCT02858258 · 870 participants (planned) · Start Jul 2016 · Primary completion May 2021
Drug: R-CHOP/R-DHAP; Ibrutinib (Induction) and 2 more · For: Mantle Cell Lymphoma
Sites: Aalborg, Denmark; Aarhus C, Denmark; Copenhagen, Denmark · 112 sites in all
- The Balloon Project for Birth InductionPivotal-lookingCompleted
Glostrup University Hospital, CopenhagenAcademic, hospital or other
NCT01255839 · 825 participants · Start Dec 2002 · Primary completion Sep 2005
Drug: Minprostin · For: Induction Time; Apgar Score; Admission to Neonatal Unit and 2 more
Sites: Glostrup Municipality, Denmark
- Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe PainPivotal-lookingCompleted
Menarini GroupIndustry
NCT01307020 · 745 participants · Start Feb 2011 · Primary completion Oct 2011
Drug: Dexketoprofen Trometamol; Dexketoprofen Trometamol and 8 more · For: Pain
Sites: Greifswald, Germany; Kiel, Germany; Budapest, Hungary · 16 sites in all
- A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy SubjectsPivotal-lookingCompleted
Bavarian NordicIndustry
NCT00316524 · 745 participants · Start Apr 2006 · Primary completion Feb 2007
Drug: MVA-BN® (IMVAMUNE); Placebo · For: Smallpox
Sites: Munich, Germany
- Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIsPivotal-lookingCompleted
Bionorica SEIndustry
NCT02639520 · 659 participants · Start Dec 2015 · Primary completion Jun 2017
Drug: Canephron® N; Fosfomycin trometamol and 2 more · For: Urinary Tract Infection
Sites: Giessen, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea23
- urinary tract infection22
- drug ineffective18
- headache18
- pain17
- fall16
- off label use16
- vomiting15
- diarrhoea14
- fatigue14
- drug interaction11
- product dose omission issue11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 12 |
| 2018 | 8 |
| 2019 | 13 |
| 2020 | 26 |
| 2021 | 13 |
| 2022 | 12 |
| 2023 | 25 |
| 2024 | 17 |
| 2025 | 17 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ketorolac tromethamine.
· Med Lett Drugs Ther 1990 · Clinical Trial
- A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation.
Arruda MP, Lima RV, Hira S, et al. · Am J Ophthalmol 2024 · Meta-Analysis, Systematic Review
- THAM for control of ICP.
Zeiler FA, Teitelbaum J, Gillman LM, et al. · Neurocrit Care 2014 · Systematic Review
- Second-Line Uterotonics for Uterine Atony: A Randomized Controlled Trial.
Cole NM, Kim JJ, Lumbreras-Marquez MI, et al. · Obstet Gynecol 2024 · Randomized Controlled Trial, Multicenter Study
- Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.
Motov S, Yasavolian M, Likourezos A, et al. · Ann Emerg Med 2017 · Comparative Study, Randomized Controlled Trial
- The use of ketorolac in the management of postoperative pain.
DeAndrade JR, Maslanka M, Maneatis T, et al. · Orthopedics 1994 · Clinical Trial, Controlled Clinical Trial
Sponsor: Pfizer · Also marketed as Tham-E
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.